Once we add adalimumab in MTX-IR RA, can we dial down MTX & still keep control? New data - now in East Asian pts (with already low MTX) says often yes, without ⬆️ADAb. Obviously RA control 1st/2nd/3rd, but prob doesn’t have to be MTX 20 forever in everyone #EULAR2022 @RheumNow https://t.co/aZ0bsgY7dC

↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx. Adjusted on smoking status, age and BMI. Shall we follow this group of patients more closely? OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k

Retrospective nation-wide italian study: Long term exposure to : 🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases 🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2 OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW

Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070 RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz

Adami et al on risk of RMDs with air pollution. Mainly RA - OR 1.4 for PM10, 1.6 for PM2.5 @RheumNow #EULAR2022 OP0071 https://t.co/zDr2jMsIWv https://t.co/f0Y2rQxWRD

• EULAR Abstract Archive

#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui

MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

• EULAR Abstract Archive

Krijbolder et al on MTX to prevent RA in clinically suspect arthralgia. No effect on arthritis free survival (80 vs 82%). Some delay in RA onset in high-risk group. But there was a sustained improvement in symptoms in MTX group @RheumNow #EULAR2022 OP0070 https://t.co/0CPIP51yQd https://t.co/kWNmw1YzrH

• EULAR Abstract Archive

Early RA - does the biologic matter? NORD-STAR: largely seropos, high CRP early RA Perhaps unsurprising abatacept shone vs TNFi or TCZ One of the few pt subgroups with plausible rationale & some data for comparative advantage. Shame it’s less & less common? #EULAR2022 @RheumNow https://t.co/CrOILKVpIp